

Special Issue

Advances in Diagnosis, Pathophysiology, and Therapy of Brain Injury

Message from the Guest Editor

This Special Issue presents the latest advances in diagnostic methods, developments in pathophysiological understanding, and (novel) therapeutic approaches to improve the treatment and management of brain injury. It aims to advance brain injury research by highlighting the latest developments in diagnostic methods (e.g., multidimensional outcome assessment, patient- and clinician-reported outcomes), pathophysiological understanding (e.g., biomarker research), and therapeutic approaches (e.g., rehabilitation, inpatient and outpatient therapy). It particularly encourages submissions focusing on research across the age span, methodological considerations, and the development of novel approaches to diagnose and treat brain injury sequelae. Cutting-edge research includes state-of-the-art diagnostic methods (e.g., multidimensional outcome assessment and advanced imaging); biomarker research; innovative therapeutic interventions (e.g., tailored rehabilitation techniques). We invite you to submit original research articles, reviews, or systematic reviews.

Guest Editor

Dr. Marina Zeldovich

Institute of Psychology, University of Innsbruck, Universitätsstrasse 15,
6020 Innsbruck, Austria

Deadline for manuscript submissions

20 January 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/175948

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).